Chugai earmarks $150M for antibody research in Singapore

Japan's Chugai Pharmaceutical is investing more than $150 million over 5 years to investigate antibodies at a new research facility in Singapore. Late last week company officials officially cut the ribbon at the new lab, which will hire about 60 scientists for the R&D effort.

Chugai plans to use its own antibody engineering technology to do the work in Singapore's Biopolis R&D hub, a heavily subsidized complex which has represented the city-state's ambitious effort to grow a new biotech industry. A*STAR Chief Scientist David Lane will be chairman of the new venture. This is Chugai's fourth research center in Asia.

Antibodies have proven to be a rich field for drug developers in recent years. Research at Deloitte Recap has underscored that experimental antibodies have a higher average rate of success than most drug fields. And developers have been following up with a second generation of new therapeutics that promises to do better, often targeting diseases along multiple pathways. 

- here's the story from Today Online
- read the report from Asian Scientist

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.